Following several control programmes and intervention strategies such as yearly school-based deworming of SAC with mebendazole/albendazole; chemotherapy with praziquantel in some identified regions in the country; nation-wide distribution of insecticide treated bed net (ITN) and LLINs; health education in schools and promoting hygiene and environmental sanitation (see Additional file 1: Figure S1) by the National programme for the control of schistosomiasis and intestinal helminthiasis and the National Malaria Control Programme (NMCP) through the Ministry Public Health, cross sectional studies were carried out in the urogenital schistosomiasis endemic focus in Muyuka Health District. This cross-sectional study which ran from March to June 2015 was a follow-up of a cross-sectional study carried out earlier [25].

The sample size for the study was determined using the formula n = Z2pq/d2 [28], where n was the sample size required; Z was 1.96, which is the standard normal deviate (for a 95% confidence interval, CI); p was 34.3%, the proportion of urogenital schistosomiasis prevalence reported previously in the area [25]; q was 1-p, the proportion of urogenital schistosomiasis negative; and d was 0.05, the acceptable error willing to be committed. The optimum minimum sample size obtained (346.3) was adjusted by 15% to a minimum of 398 in case of sample loss due to transportation difficulties and non-compliance by participants to provide all three samples. With respect to sampling, a representative sample from each primary school and study site was selected at random by balloting from each class accounting for the numbers above the calculated sample size. Likoko village with the highest number of primary schools had the highest number of study participants followed by Ikata and Bafia.

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.